BCL2 and prostate carcinoma: Moreover, in two individual prostate cancer studies 46, 47, we found that in patients with previous taxane treatment, higher levels of prostate specific antigen (greater than median) correlated with a higher level of BCL2 mRNA (Figure 6D).